Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

Mirabegron, a β3-adrenoreceptor agonist, has demonstrated long-term safety, tolerability, and persistence of effect in this 12-mo study in patients with overactive bladder.